Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 1,300 Shares

Key Points

• COO Jeremy Chadwick sold 1,300 Kymera shares on April 15 at an average price of $90, cutting his stake by 2.08% to 61,202 shares valued at about $5.51 million.
• Kymera's latest quarter missed expectations—($0.97) EPS vs. ($0.77) expected and $2.87M revenue vs. $14.8M expected—resulting in steep negative margins, while analysts maintain a Moderate Buy consensus with a $118.90 price target.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 1,300 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $90.00, for a total value of $117,000.00. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares of the company's stock, valued at approximately $5,508,180. The trade was a 2.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded down $2.86 on Thursday, hitting $86.14. The company's stock had a trading volume of 554,950 shares, compared to its average volume of 732,626. The stock's 50-day moving average is $83.69 and its two-hundred day moving average is $74.15. The company has a market capitalization of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12 month low of $24.72 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company's revenue was down 60.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KYMR. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a "buy" rating and a $110.00 price objective on the stock. BTIG Research cut their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Citigroup raised their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. B. Riley Financial increased their price objective on Kymera Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Finally, UBS Group boosted their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a research report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $118.90.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Rockefeller Capital Management L.P. boosted its position in Kymera Therapeutics by 21,538.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company's stock valued at $1,987,000 after buying an additional 25,415 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the 4th quarter valued at $198,000. Virtu Financial LLC acquired a new position in Kymera Therapeutics during the 4th quarter valued at about $2,123,000. T. Rowe Price Investment Management Inc. lifted its position in Kymera Therapeutics by 3.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company's stock valued at $49,001,000 after purchasing an additional 18,524 shares during the period. Finally, Invesco Ltd. lifted its position in Kymera Therapeutics by 46.3% during the 4th quarter. Invesco Ltd. now owns 116,747 shares of the company's stock valued at $9,084,000 after purchasing an additional 36,940 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.